# NLS Pharmaceutics Ltd. (NLSP) Source: https://www.quantisnow.com/company/NLSP Generated: 2026-11-13T17:47:12.249Z - Ticker: NLSP - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2021 - Website: nlspharma.com ## About NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland. ## Latest NLSP news and filings - 2025-11-17 12:00 UTC [Leadership Update] [NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute](https://www.quantisnow.com/insight/newcelx-strengthens-scientific-advisory-board-with-appointment-of-jeremy-shefner-6281999) - 2025-11-07 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6267157) - 2025-11-06 02:44 UTC [SEC Form POS AM filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-nls-pharmaceutics-ltd-6263740) - 2025-11-04 23:57 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-nls-pharmaceutics-ltd-6260364) - 2025-11-04 12:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6257968) - 2025-11-03 13:47 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6255752) - 2025-10-30 20:56 UTC [Amendment: SEC Form 25-NSE/A filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-25-nsea-filed-by-nls-pharmaceutics-ltd-6253100) - 2025-10-30 20:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6252790) - 2025-10-30 20:15 UTC [NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger](https://www.quantisnow.com/insight/nls-pharmaceutics-ltd-and-kadimastem-ltd-announce-completion-of-merger-6252728) - 2025-10-30 11:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6251193) - 2025-10-30 11:00 UTC [NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs](https://www.quantisnow.com/insight/nls-pharmaceutics-expands-cns-pipeline-with-aex-6xx-series-developed-by-6251112) - 2025-10-29 11:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6249063) - 2025-10-29 11:00 UTC [NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger](https://www.quantisnow.com/insight/nls-pharmaceutics-and-kadimastem-highlight-continued-bird-foundation-support-for-6248953) - 2025-10-29 01:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6248737) - 2025-10-29 10:00 UTC [NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem](https://www.quantisnow.com/insight/nls-pharmaceutics-ltd-announces-1-for-10-reverse-share-split-and-name-6248675) - 2025-10-29 07:53 UTC [NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares](https://www.quantisnow.com/insight/nls-pharmaceutics-and-kadimastem-announce-completion-of-material-conditions-precedent-6248645) - 2025-10-28 20:37 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6248239) - 2025-10-27 11:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6245262) - 2025-10-27 11:00 UTC [NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies](https://www.quantisnow.com/insight/nls-pharmaceutics-and-kadimastem-announce-strategic-collaboration-between-kadimastem-and-6245224) - 2025-10-24 20:01 UTC [SEC Form POS AM filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-nls-pharmaceutics-ltd-6244493) - 2025-10-23 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6242389) - 2025-10-23 10:01 UTC [NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025](https://www.quantisnow.com/insight/nls-and-kadimastem-announce-receipt-of-nasdaq-approval-merger-expected-6242327) - 2025-10-17 20:38 UTC [SEC Form POS AM filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-nls-pharmaceutics-ltd-6237186) - 2025-10-10 00:44 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6229445) - 2025-10-04 01:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6223675) - 2025-10-01 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nls-pharmaceutics-ltd-6216853) - 2025-09-30 11:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6215243) - 2025-09-30 11:00 UTC [NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting](https://www.quantisnow.com/insight/nls-pharmaceutics-shareholders-approve-merger-with-kadimastem-and-related-proposals-6215225) - 2025-09-25 20:49 UTC [SEC Form F-1] [SEC Form F-1 filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-f-1-filed-by-nls-pharmaceutics-ltd-6212140) - 2025-09-19 20:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6206641) - 2025-09-10 21:11 UTC [SEC Form 424B3] [SEC Form 424B3 filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-nls-pharmaceutics-ltd-6196885) - 2025-09-10 10:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6195758) - 2025-09-10 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nls-pharmaceutics-ltd-6195721) - 2025-09-10 10:00 UTC [Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger](https://www.quantisnow.com/insight/kadimastem-and-nls-pharmaceutics-announce-effectiveness-of-sec-registration-statement-6195698) - 2025-09-04 12:40 UTC [SEC Form 425] [SEC Form 425 filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-425-filed-by-nls-pharmaceutics-ltd-6189463) - 2025-09-04 12:37 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6189461) - 2025-09-04 11:38 UTC [NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients](https://www.quantisnow.com/insight/nls-pharmaceutics-and-kadimastem-announce-a-hong-kong-patent-covering-6189247) - 2025-09-03 21:26 UTC [Amendment: SEC Form F-4/A filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-f-4a-filed-by-nls-pharmaceutics-ltd-6188648) - 2025-08-29 20:02 UTC [SEC Form 425] [SEC Form 425 filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-425-filed-by-nls-pharmaceutics-ltd-6183657) - 2025-08-29 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by NLS Pharmaceutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nls-pharmaceutics-ltd-6183645) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NLSP - Earnings history: https://www.quantisnow.com/earnings/NLSP - Dividend history: https://www.quantisnow.com/dividends/NLSP - Insider transactions: https://www.quantisnow.com/insiders/NLSP - Options chain: https://www.quantisnow.com/options/NLSP - SEC 8-K filings only: https://www.quantisnow.com/company/NLSP/8-k - RSS and alerts for NLSP: https://www.quantisnow.com/docs/rss-feeds.md